Lentivirus mediated delivery of neurosin promotes clearance of wild-type α-synuclein and reduces the pathology in an α-synuclein model of LBD

Molecular Therapy

Volumn 21, Issue 1, 2013, Pages 31-41

  Spencer, Brian ^a   Michael, Sarah ^a   Shen, Jay ^a   Kosberg, Kori ^a   Rockenstein, Edward ^a   Patrick, Christina ^a   Adame, Anthony ^a   Masliah, Eliezer ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; KALLIKREIN 6; LENTIVIRUS VECTOR;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BRAIN LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; FEMALE; GENE; HUMAN; LENTIVIRINAE; MALE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOUSE; NEUROSIN GENE; NONHUMAN; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; VIRAL GENE THERAPY; WILD TYPE;

LENTIVIRUS; MUS;

EID: 84871921645     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.66     Document Type: Article

References (50)

1. Takeda, A, Hashimoto, M, Mallory, M, Sundsumo, M, Hansen, L, Sisk, A et al. (1998).Abnormal distribution of the non-Abeta component of Alzheimer's disease amyloidprecursor/alpha-synuclein in Lewy body disease as revealed by proteinase K andformic acid pretreatment. Lab Invest 78: 1169-1177. (Pubitemid 28440832)
2. Wakabayashi, K, Matsumoto, K, Takayama, K, Yoshimoto, M and Takahashi, H (1997).NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease.Neurosci Lett 239: 45-48. (Pubitemid 28055846)
3. Masliah, E, Iwai, A, Mallory, M, Uéda, K and Saitoh, T (1996). Altered presynapticprotein NACP is associated with plaque formation and neurodegeneration inAlzheimer's disease. Am J Pathol 148: 201-210. (Pubitemid 26019656)
4. Uéda, K, Fukushima, H, Masliah, E, Xia, Y, Iwai, A, Yoshimoto, M et al. (1993).Molecular cloning of cDNA encoding an unrecognized component of amyloid inAlzheimer disease. Proc Natl Acad Sci USA 90: 11282-11286. (Pubitemid 23354413)
5. Lashuel, HA, Petre, BM, Wall, J, Simon, M, Nowak, RJ, Walz, T et al. (2002). Alphasynuclein,especially the Parkinson's disease-associated mutants, forms pore-likeannular and tubular protofibrils. J Mol Biol 322: 1089-1102. (Pubitemid 35266514)
6. Giasson, BI, Duda, JE, Murray, IV, Chen, Q, Souza, JM, Hurtig, HI et al. (2000).Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitrationin synucleinopathy lesions. Science 290: 985-989.
7. Shimura, H, Schlossmacher, MG, Hattori, N, Frosch, MP, Trockenbacher, A, Schneider,R et al. (2001). Ubiquitination of a new form of alpha-synuclein by parkin from humanbrain: implications for Parkinson's disease. Science 293: 263-269. (Pubitemid 32694735)
8. Cuervo, AM, Stefanis, L, Fredenburg, R, Lansbury, PT and Sulzer, D (2004). Impaireddegradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science305: 1292-1295. (Pubitemid 39129234)
9. Spencer, B, Potkar, R, Trejo, M, Rockenstein, E, Patrick, C, Gindi, R et al. (2009). Beclin1 gene transfer activates autophagy and ameliorates the neurodegenerative pathologyin alpha-synuclein models of Parkinson's and Lewy body diseases. J Neurosci 29:13578-13588.
10. McLean, PJ, Kawamata, H, Ribich, S and Hyman, BT (2000). Membrane associationand protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson'sdisease-linked mutations. J Biol Chem 275: 8812-8816. (Pubitemid 30180236)
11. Sharon, R, Goldberg, MS, Bar-Josef, I, Betensky, RA, Shen, J and Selkoe, DJ (2001).alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fattyacids, and shows homology to the fatty acid-binding proteins. Proc Natl Acad Sci USA98: 9110-9115. (Pubitemid 32743877)
12. Iwai, A, Masliah, E, Yoshimoto, M, Ge, N, Flanagan, L, de Silva, HA et al. (1995).The precursor protein of non-A beta component of Alzheimer's disease amyloid is apresynaptic protein of the central nervous system. Neuron 14: 467-475.
13. Scott, DA, Tabarean, I, Tang, Y, Cartier, A, Masliah, E and Roy, S (2010). Apathologic cascade leading to synaptic dysfunction in alpha-synuclein-inducedneurodegeneration. J Neurosci 30: 8083-8095.
14. Lee, HJ, Patel, S and Lee, SJ (2005). Intravesicular localization and exocytosis of alphasynucleinand its aggregates. J Neurosci 25: 6016-6024. (Pubitemid 40911433)
15. Ogawa, K, Yamada, T, Tsujioka, Y, Taguchi, J, Takahashi, M, Tsuboi, Y et al. (2000).Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues ofAlzheimer's disease and Parkinson's disease. Psychiatry Clin Neurosci 54: 419-426.
16. Iwata, A, Maruyama, M, Akagi, T, Hashikawa, T, Kanazawa, I, Tsuji, S et al. (2003).Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesisof synucleinopathies. Hum Mol Genet 12: 2625-2635. (Pubitemid 37304685)
17. Tatebe, H, Watanabe, Y, Kasai, T, Mizuno, T, Nakagawa, M, Tanaka, M et al. (2010).Extracellular neurosin degrades a-synuclein in cultured cells. Neurosci Res 67: 341-346.
18. Kasai, T, Tokuda, T, Yamaguchi, N, Watanabe, Y, Kametani, F, Nakagawa, M et al.(2008). Cleavage of normal and pathological forms of alpha-synuclein by neurosin invitro. Neurosci Lett 436: 52-56.
19. Petraki, CD, Karavana, VN, Skoufogiannis, PT, Little, SP, Howarth, DJ, Yousef, GM et al.(2001). The spectrum of human kallikrein 6 (zyme/protease M/neurosin) expressionin human tissues as assessed by immunohistochemistry. J Histochem Cytochem 49:1431-1441. (Pubitemid 33000802)
20. Yamanaka, H, He, X, Matsumoto, K, Shiosaka, S and Yoshida, S (1999). Protease M/neurosin mRNA is expressed in mature oligodendrocytes. Brain Res Mol Brain Res 71:217-224. (Pubitemid 29492966)
21. Little, SP, Dixon, EP, Norris, F, Buckley, W, Becker, GW, Johnson, M et al. (1997).Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer'sdisease brain. J Biol Chem 272: 25135-25142. (Pubitemid 27415697)
22. Yamashiro, K, Tsuruoka, N, Kodama, S, Tsujimoto, M, Yamamura, Y, Tanaka, Tet al. (1997). Molecular cloning of a novel trypsin-like serine protease (neurosin)preferentially expressed in brain. Biochim Biophys Acta 1350: 11-14. (Pubitemid 27025924)
23. Blaber, SI, Yoon, H, Scarisbrick, IA, Juliano, MA and Blaber, M (2007). The autolyticregulation of human kallikrein-related peptidase 6. Biochemistry 46: 5209-5217.
24. Yoon, H, Blaber, SI, Evans, DM, Trim, J, Juliano, MA, Scarisbrick, IA et al. (2008).Activation profiles of human kallikrein-related peptidases by proteases of thethrombostasis axis. Protein Sci 17: 1998-2007.
25. Magklara, A, Mellati, AA, Wasney, GA, Little, SP, Sotiropoulou, G, Becker, GWet al. (2003). Characterization of the enzymatic activity of human kallikrein 6:Autoactivation, substrate specificity, and regulation by inhibitors. Biochem Biophys ResCommun 307: 948-955. (Pubitemid 36871664)
26. Murray, IV, Giasson, BI, Quinn, SM, Koppaka, V, Axelsen, PH, Ischiropoulos, H etal. (2003). Role of alpha-synuclein carboxy-terminus on fibril formation in vitro.Biochemistry 42: 8530-8540. (Pubitemid 36875420)
27. Tofaris, GK, Garcia Reitböck, P, Humby, T, Lambourne, SL, O'Connell, M, Ghetti, B etal. (2006). Pathological changes in dopaminergic nerve cells of the substantia nigraand olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120):implications for Lewy body disorders. J Neurosci 26: 3942-3950. (Pubitemid 44315414)
28. Krüger, R, Kuhn, W, Müller, T, Woitalla, D, Graeber, M, Kösel, S et al. (1998). Ala30Promutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18:106-108.
29. Polymeropoulos, MH, Lavedan, C, Leroy, E, Ide, SE, Dehejia, A, Dutra, A et al. (1997).Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.Science 276: 2045-2047. (Pubitemid 27443610)
30. Hashimoto, M, Rockenstein, E and Masliah, E (2003). Transgenic models of alphasynucleinpathology: past, present, and future. Ann N Y Acad Sci 991: 171-188. (Pubitemid 36793813)
31. Menendez-Gonzalez, M, Castro-Santos, P, Suarez, A, Calatayud, MT, Perez-Pinera,P, Martinez, M et al. (2008). Value of measuring plasmatic levels of neurosin in thediagnosis of Alzheimer's disease. J Alzheimers Dis 14: 59-67. (Pubitemid 352039017)
32. Ashby, EL, Kehoe, PG and Love, S (2010). Kallikrein-related peptidase 6 in Alzheimer'sdisease and vascular dementia. Brain Res 1363: 1-10.
33. Ling, L, Hou, Q, Xing, S, Yu, J, Pei, Z and Zeng, J (2008). Exogenous kallikreinenhances neurogenesis and angiogenesis in the subventricular zone and the periinfarctionregion and improves neurological function after focal cortical infarction inhypertensive rats. Brain Res 1206: 89-97.
34. Fortin, DL, Troyer, MD, Nakamura, K, Kubo, S, Anthony, MD and Edwards, RH(2004). Lipid rafts mediate the synaptic localization of alpha-synuclein. J Neurosci 24:6715-6723. (Pubitemid 38993891)
35. Chandra, S, Fornai, F, Kwon, HB, Yazdani, U, Atasoy, D, Liu, X et al. (2004). Doubleknockoutmice for alpha-and beta-synucleins: effect on synaptic functions. Proc NatlAcad Sci USA 101: 14966-14971. (Pubitemid 39410782)
36. Crowther, RA, Jakes, R, Spillantini, MG and Goedert, M (1998). Synthetic filamentsassembled from C-terminally truncated alpha-synuclein. FEBS Lett 436: 309-312. (Pubitemid 28482951)
37. Giasson, BI, Murray, IV, Trojanowski, JQ and Lee, VM (2001). A hydrophobic stretchof 12 amino acid residues in the middle of alpha-synuclein is essential for filamentassembly. J Biol Chem 276: 2380-2386.
38. Mishizen-Eberz, AJ, Guttmann, RP, Giasson, BI, Day, GA 3rd, Hodara, R, Ischiropoulos,H et al. (2003). Distinct cleavage patterns of normal and pathologic forms of alphasynucleinby calpain I in vitro. J Neurochem 86: 836-847. (Pubitemid 36988796)
39. Li, J, Uversky, VN and Fink, AL (2002). Conformational behavior of human alphasynucleinis modulated by familial Parkinson's disease point mutations A30P and A53T.Neurotoxicology 23: 553-567. (Pubitemid 36527676)
40. Crews, L, Spencer, B, Desplats, P, Patrick, C, Paulino, A, Rockenstein, E et al. (2010).Selective molecular alterations in the autophagy pathway in patients with Lewy bodydisease and in models of alpha-synucleinopathy. PLoS ONE 5: e9313.
41. Sung, JY, Park, SM, Lee, CH, Um, JW, Lee, HJ, Kim, J et al. (2005). Proteolytic cleavageof extracellular secreted {alpha}-synuclein via matrix metalloproteinases. J Biol Chem280: 25216-25224. (Pubitemid 40934615)
42. Spencer, B, Rockenstein, E, Crews, L, Marr, R and Masliah, E (2007). Novel strategiesfor Alzheimer's disease treatment. Expert Opin Biol Ther 7: 1853-1867. (Pubitemid 350247488)
43. Braak, H and Braak, E (2000). Pathoanatomy of Parkinson's disease. J of Neurology 247Suppl 2: II3-10.
44. Hansen, LA, Masliah, E, Quijada-Fawcett, S and Rexin, D (1991). Entorhinalneurofibrillary tangles in Alzheimer disease with Lewy bodies. Neurosci Lett 129:269-272.
45. McKeith, IG (2006). Consensus guidelines for the clinical and pathologic diagnosisof dementia with Lewy bodies (DLB): report of the Consortium on DLB InternationalWorkshop. J Alzheimers Dis 9(3 Suppl): 417-423. (Pubitemid 44253336)
46. Jellinger, KA and Bancher, C (1998). Neuropathology of Alzheimer's disease: a criticalupdate. J Neural Transm Suppl 54: 77-95.
47. Tiscornia, G, Singer, O and Verma, IM (2006). Production and purification of lentiviralvectors. Nat Protoc 1: 241-245.
48. Spencer, B, Marr, RA, Gindi, R, Potkar, R, Michael, S, Adame, A et al. (2011). Peripheraldelivery of a CNS targeted, metalo-protease reduces a toxicity in a mouse model ofAlzheimer's disease. PLoS ONE 6: e16575.
49. Masliah, E (2000). The role of synaptic proteins in Alzheimer's disease. Ann N Y AcadSci 924: 68-75. (Pubitemid 32050185)
50. Rockenstein, E, Mallory, M, Hashimoto, M, Song, D, Shults, CW, Lang, I et al. (2002).Differential neuropathological alterations in transgenic mice expressing alphasynucleinfrom the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res68: 568-578. (Pubitemid 34575622)